AZN.L - AstraZeneca PLC
| Previous close | 5,428.00 |
| Open | 5,469.00 |
| Bid | 5,400.00 x 6100 |
| Ask | 5,500.00 x 13000 |
| Day's range | 5,435.00 - 5,490.00 |
| 52-week range | 4,260.00 - 5,520.00 |
| Volume | 1,901,729 |
| Avg. volume | 2,326,843 |
| Market cap | 69.387B |
| Beta | 0.98 |
| PE ratio (TTM) | 23.11 |
| EPS (TTM) | 237.00 |
| Earnings date | 26 Jul 2018 |
| Forward dividend & yield | 2.02 (4.06%) |
| Ex-dividend date | 2018-02-15 |
| 1y target est | 72.97 |
- Reuters•6 hours ago
Oil weighs on FTSE, Kingfisher shines
By Julien Ponthus LONDON (Reuters) - A slump in oil prices hit British majors on Friday, limiting the gains of the FTSE 100 benchmark index while Kingfisher shone after Australia's Wesfarmers (WES.AX) ...
- Reuters - UK Focus•6 hours ago
Oil weighs on Britain's FTSE, Kingfisher shines
A slump in oil prices hit British majors on Friday, limiting the gains of the FTSE 100 benchmark index while Kingfisher shone after Australia's Wesfarmers said it would sell rival UK home improvement chain ...
- Reuters - UK Focus•13 hours ago
Britain's FTSE rebounds, Kingfisher jumps as Homebase changes hands
Kingfisher led a rebound in UK shares on Friday amid relief on global markets about Pyongyang's measured response to the canceling of the summit between the United States and North Korea. At 0900 GMT, ...
- Reuters•15 hours ago
AstraZeneca cancer drug hits second goal by extending survival
AstraZeneca's (AZN.L) immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch. Imfinzi is the first immunotherapy to be approved in this setting, giving AstraZeneca a chance to intervene relatively early in lung cancer.
- Reuters - UK Focus•15 hours ago
AstraZeneca cancer drug hits second goal by extending survival
AstraZeneca (NYSE: AZN - news) 's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch. Imfinzi is the first immunotherapy to be approved in this setting, giving AstraZeneca a chance to intervene relatively early in lung cancer. Analysts believe using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity and the latest overall survival (OS) data should underline the drug's potential.
- MarketWatch•4 days ago
U.K. stocks log record close as U.S.-China ease trade-war tensions
U.K. stocks rose sharply on Monday, scoring a record close, as traders welcomed news over the weekend that China and the U.S. reached an agreement that eases trade tensions between the world’s two largest economies. The FTSE 100 index (^FTSE) rose 1% to end at 7,859.17, taking out its previous closing high of 7,787.97, hit last Thursday. A weaker pound tends to boost the FTSE 100, as the index’s components conduct the bulk of their business overseas and a softening in sterling lifts revenue when converted back into the U.K. currency.
- Zacks•4 days ago
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
Reuters•4 days agoAstraZeneca potassium drug finally approved, threatening Vifor
The decision by U.S. regulators to finally approve AstraZeneca's (AZN.L) much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products. The U.S. Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, two times previously, casting doubt over AstraZeneca's decision to buy its original developer ZS Pharma for $2.7 billion (2 billion pounds) in 2015. Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma's (VIFN.S) rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.
- Reuters - UK Focus•4 days ago
AstraZeneca potassium drug finally approved, threatening Vifor
The decision by U.S. regulators to finally approve AstraZeneca (NYSE: AZN - news) 's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products. The U.S. Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, two times previously, casting doubt over AstraZeneca's decision to buy its original developer ZS Pharma (NasdaqGM: ZSPH - news) for $2.7 billion in 2015. Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma's rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.
- Reuters - UK Focus•5 days ago
BUZZ-AstraZeneca: FDA approves co's potassium control drug
** Shares of AstraZeneca up 2 pct after co's potassium control drug approved in the US ** Stock top pct gainer on the FTSE 100 ** Co's Lokelma approved in the US for the treatment of adults with hyperkalaemia, ...
- Investor's Business Daily•7 days ago
AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?
AstraZeneca dipped early Friday after the U.K.-based pharmaceutical company lagged first-quarter expectations for sales and core earnings.
- Zacks•7 days ago
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
Motley Fool•7 days agoAstrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript
AZN earnings call for the period ending March 31, 2018.
Reuters•7 days agoAstraZeneca pay report rejected by 35 percent of shareholders
More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.
Reuters•7 days agoAstraZeneca pay report rejected by 35 percent of shareholders
More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.
- Reuters - UK Focus•7 days ago
AstraZeneca pay report rejected by 35 pct of shareholders
More than a third of AstraZeneca (Swiss: AZN.SW - news) shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca (NYSE: AZN - news) engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.
- MarketWatch•7 days ago
U.K. stocks fall from record as AstraZeneca, mining stocks decline
FTSE 100 on track for longest weekly win run since 2005ReutersAstraZeneca shares are losing ground Friday. U.K. stocks ended lower on Friday, pulling back from the previous session’s record close, as shares of AstraZeneca declined following the heavyweight drugmaker’s earnings report, and as shares in mining companies skidded in the wake of a selloff in metals prices. The FTSE 100 index (^FTSE) dropped 0.1% to close at 7,778.79, breaking a three-day winning streak.
Reuters•7 days agoCommodities help FTSE seal eight-week winning streak
Britain's leading stock index posted its eighth straight week of gains despite dipping slightly on Friday as investor enthusiasm waned following the previous day's record close. The FTSE 100 ended the session down 0.1 percent at 7,778.79 points, in line with the FTSE 250 which hit a fresh record earlier in the session before turning lower. The FTSE sealed its longest winning streak in 13 years, marking a strong comeback for British stocks.
- Reuters - UK Focus•7 days ago
Commodities help FTSE seal eight-week winning streak
Britain's leading stock index posted its eighth straight week of gains despite dipping slightly on Friday as investor enthusiasm waned following the previous day's record close. The FTSE 100 ended the ...
- Reuters - UK Focus•7 days ago
LIVE MARKETS-Closing snapshot: STOXX posts best weekly streak since 2014
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...
- Reuters - UK Focus•7 days ago
LIVE MARKETS-France vs Germany: here's a reality-check for Macron believers
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...
- Reuters - UK Focus•7 days ago
LIVE MARKETS-Italy: no surprises there
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...
- Reuters - UK Focus•7 days ago
LIVE MARKETS-Strong dollar a boost for European equities
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...
- Zacks•7 days ago
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
- Reuters - UK Focus•7 days ago
LIVE MARKETS-Why European shares can relax about bond yields (and the U.S. can't)
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...
